Table 2.
Baseline characteristics—switched population
| Switched patientsa | Rheumatology cohort | Gastroenterology cohort | |||
|---|---|---|---|---|---|
| RA N = 39 |
PsA N = 30 |
AS N = 119 |
CD N = 108 |
UC N = 14 |
|
| Data capturing, n (%) | |||||
| Fully prospective | 30 (76.9%) | 21 (70.0%) | 82 (68.9%) | 72 (66.7%) | 11 (78.6%) |
| Shifted prospective | 2 (5.1%) | 2 (6.7%) | 7 (5.9%) | 14 (13.0%) | 2 (14.3%) |
| Fully retrospective | 7 (17.9%) | 7 (23.3%) | 30 (25.2%) | 22 (20.4%) | 1 (7.1%) |
| Age, years, mean (SD) | 60.7 (12.2) | 52.8 (13.6) | 48.0 (13.3) | 43.0 (14.3) | 37.9 (11.7) |
| Female patients, n (%) | 30 (76.9%) | 11 (36.7%) | 45 (37.8%) | 44 (40.7%) | 5 (35.7%) |
| Weight, kg, mean (SD) | 68.3 (12.7) | 80.4 (16.7) | 76.1 (16.4) | 75.2 (17.7) | 73.0 (19.1) |
| Height, cm, mean (SD) | 163.8 (9.4) | 170.8 (8.3) | 169.8 (9.7) | 170.9 (8.9) | 171.1 (9.5) |
| BMI, kg/m2, mean (SD) | 25.4 (4.5) | 27.7 (5.6) | 26.5 (5.7) | 25.7 (5.3) | 24.7 (5.2) |
| Disease duration, years, mean (SD) | 20.3 (12.4) | 11.4 (8.2) | 14.3 (12.4) | 12.9 (9.3) | 9.6 (7.8) |
| Patients with comorbidities at baseline, n (%)A | 20 (51.3%) | 17 (56.7%) | 58 (48.7%) | 42 (38.9%) | 3 (21.4%) |
| Patients with co-treatments at baseline, n (%)A | 23 (59.0%) | 8 (26.7%) | 10 (8.4%) | 20 (18.5%) | 2 (14.3%) |
| Prior adalimumab, n (%) | |||||
| Reference adalimumab only | 37 (94.9%) | 29 (96.7%) | 113 (95.0%) | 103 (95.4%) | 13 (92.9%) |
| Biosimilar adalimumab only | 0 (0.0%) | 1 (3.3%) | 3 (2.5%) | 2 (1.9%) | 0 (0.0%) |
| Reference and biosimilar adalimumab | 2 (5.1%) | 0 (0.0%) | 3 (2.5%) | 3 (2.7%) | 1 (7.1%) |
| Prior exposure to other biologics, n (%) | |||||
| Infliximab | 1 (2.6%) | 3 (10.0%) | 5 (4.2%) | 19 (17.6%) | 3 (21.4%) |
| Etanercept | 2 (5.1%) | 3 (10.0%) | 14 (11.8%) | 1 (0.9%) | – |
| Ustekinumab | – | – | – | 1 (0.9%) | – |
| Golimumab | – | 1 (3.3%) | – | – | – |
| Certolizumab pegol | 1 (2.6%) | 2 (6.7%) | 2 (1.7%) | – | – |
| Tocilizumab | 1 (2.6%) | – | – | – | – |
| Secukinumab | – | – | 1 (0.8%) | – | – |
| JAK inhibitors | 1 (2.6%) | – | – | – | – |
| Patients taking methotrexate at baseline, n (%) | 18 (46.2%) | 6 (20.0%) | 6 (5.0%) | 5 (4.6%) | – |
| Patients taking azathioprine at baseline, n (%) | – | – | – | 8 (7.4%) | – |
| Number of patients with disease activity scores at baseline, n (%) |
DAS28-ESR 14 (35.9%) DAS28-CRP 5 (12.8%) |
BASDAI 8 (26.7%) DAS28-ESR 3 (10.0%) DAS28-CRP 4 (13.3%) |
BASDAI 57 (47.9%) |
HBI 81 (75.0%) |
SCCAI 8 (57.1%) |
| Categorical disease activity scores, n (%) | |||||
| Remission | 15 (78.9%) | 3 (20.0%) | N/A | 68 (84.0%) | N/A |
| Low/mild disease activity | – | 9 (60.0%) | 36 (63.2%) | 7 (8.6%) | 8 (100%) |
| Moderate disease activity | 3 (15.8%) | 2 (13.3%) | N/A | 6 (7.4%) | N/A |
| Data capturing, n (%) | |||||
| Fully prospective | 30 (76.9%) | 21 (70.0%) | 82 (68.9%) | 72 (66.7%) | 11 (78.6%) |
| High disease activity | 1 (5.3%) | 1 (6.7%) | 21 (36.8%) | – | – |
AS ankylosing spondylitis, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, CD Crohn’s disease, CRP C-reactive protein, DAS28 Disease Activity Score (28 joint), ESR erythrocyte sedimentation rate, HBI Harvey–Bradshaw Index, N/A not applicable, PsA psoriatic arthritis, RA rheumatoid arthritis, SD standard deviation, SCCAI Simple Clinical Colitis Activity Index, shifted prospective part prospective/part retrospective, UC ulcerative colitis
aBoth from reference and from biosimilar adalimumab
AFull listings of comorbidities and co-treatments reported at baseline are provided in Supplementary Tables S3A & S3B